Status:
COMPLETED
Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
Lead Sponsor:
UCB Pharma SA
Collaborating Sponsors:
ReSearch Pharmaceutical Services, Inc.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The main objective is to assess Health-Related Quality of Life (HRQoL) according to physical function, as measured by a specific Questionnaire (Health Assessment Questionnaire), in Rheumatoid Arthriti...
Detailed Description
An open-label, prospective, and post-authorization observational study. This non-interventional study is designed to establish the importance of the measurement of HRQoL data and patient-reported outc...
Eligibility Criteria
Inclusion
- Patient is male or female, aged 18 years or older
- Patient has active Rheumatoid Arthritis according to American College of Rheumatology (ACR) criteria with duration ≥ 3 months
- Patient has DAS28 (ESR) \> 4.5 and CRP \> 1.0 mg/dl at Baseline
- Patient has failed previous Disease Modifying Anti-Rheumatic Drugs (DMARDs) including Methotrexate treatment
- Patient has initiated treatment with subcutaneous anti-Tumour Necrosis Factor alpha (anti-TNFα) CZP, administered every 2 weeks
- Patient has no other prior anti-TNFα treatment (Naïve Patient) or CZP is administered after failure to the first anti-TNFα treatment (First Switch Patient)
- Patient is considered reliable and capable of adhering to the protocol, visit schedule or medication intake according to the judgment of the physician
- Patient has signed and dated a written informed consent form
- The patient's treatment must be within the terms of Summary of Product Characteristics (SmPC)
Exclusion
- Patient has a known hypersensitivity to the active substance or to any of the excipients
- Patient has active Tuberculosis or other severe infections such as Sepsis or Opportunistic Infections
- Patient has moderate to severe Heart Failure (New York Heart Association (NHYA) classes III/IV)
- Patient has any medical or psychiatric condition that, in the opinion of the physician, could jeopardize or would compromise the patient's ability to participate in this study or to complete the scheduled questionnaires
- Pregnant women or women of childbearing potential who are not using adequate contraception to prevent pregnancy
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT01526434
Start Date
January 1 2012
End Date
March 1 2014
Last Update
March 19 2014
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
11
A Coruña, Spain
2
15
Barcelona, Spain
3
20
Barcelona, Spain
4
4
Barcelona, Spain